Morgenstern, Daniel A.

Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes

Muir, E. M., Adcock, K. H., Morgenstern, D. A., Clayton, R., von Stillfried, N., Rhodes, K., Ellis, C., Fawcett, J. W., & Rogers, J. H. (2002) · Molecular Brain Research

Protease and Inhibitor MechanismsTraumatic Brain Injury and Neurovascular Disturbances

Cited by 206

Checkpoint immunotherapy in pediatrics: here, gone, and back again

Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., & Davis, K. L. (2022) · American Society of Clinical Oncology Educational Book

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 53

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma

Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 28

Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial

Loeb, D. M., Lee, J. W., Morgenstern, D. A., Samson, Y., Uyttebroeck, A., Lyu, C. J., Van Damme, A., Nysom, K., Macy, M. E., Zorzi, A. P., et al. (2022) · Cancer Immunology Immunotherapy

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 21

Phase I dose-finding study for melatonin in pediatric oncology patients with relapsed solid tumors

Johnston, D. L., Zupanec, S., Nicksy, D., Morgenstern, D., Narendran, A., Deyell, R. J., Samson, Y., Wu, B., & Baruchel, S. (2019) · Pediatric Blood & Cancer

Circadian rhythm and melatoninPharmaceutical studies and practices

Cited by 8